Watson Farley & Williams (“WFW”) advised Sartorius AG (“Sartorius”) on a €8.2m Series A financing round for Curexsys GmbH (“Curexsys”), a Germany-based technology leader specialising in the emerging field of therapeutic exosomes, with Evotec SE investing alongside Sartorius.
Curexsys produces proprietary isolation technology for exosomes based on a traceless immune-affinity process. This process is different from commonly used antibody-based processes and enables Curexsys to overcome a key hurdle in exosome preparation, i.e. remaining antibodies in the final preparation. Curexsys was founded by Dr Herbert Stadler, a serial biotech entrepreneur, and Dr Jens Gruber, a former group leader of Medical RNA Biology who acts as the Curexsys’ Chief Scientific Officer.
Sartorius is an international life sciences company based in Göttingen, Germany. In addition to supplying pharmaceutical laboratory equipment worldwide, Sartorius is dedicated to accelerating medical discoveries and simplifying drug production.
The WFW Germany Corporate team that advised Sartorius was led by Frankfurt Partner Dr Christoph Naumann, supported by Frankfurt Associate Matthias Strecker. Counsel Torge Rademacher and Associate Desideria-Alexia Pohl (both Hamburg) advised on the IP law aspects of the financing round.
Christoph commented: “I’m delighted that we were able to help our client successfully close this financing round which enables Curexsys to accelerate the commercialisation of its exosome isolation technology. We are very pleased that our long-standing client Sartorius opted again for WFW to advise them”.
